Evidence map›Paper›PMID 38815020›Full record

ArticleScience (New York, N.Y.)2024

Stem-cell states converge in multistage cutaneous squamous cell carcinoma development.

Mark A Taylor, Eve Kandyba, Kyle Halliwill, Reyno Delrosario, Matvei Khoroshkin, Hani Goodarzi, David Quigley, Yun Rose Li, Di Wu, Saumya R Bollam and 3 more

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Protective Potential of Terpenoid-RichJournal of cancer prevention · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Cell lineage tracing: Methods, applications, and challenges.Quantitative biology (Beijing, China) · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mark A Taylor *Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0003-2266-7917
Eve Kandyba *Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-9219-5284
Kyle HalliwillHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.
Reyno DelrosarioHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.
Matvei KhoroshkinHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-1744-6792
Hani GoodarziHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-9648-8949
David QuigleyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-4726-1473
Yun Rose LiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-8077-4975
Di WuHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.
Saumya R BollamBiomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA 94518, USA.ORCID 0000-0002-6903-4618
Olga K MirzoevaHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-5564-1564
Rosemary J AkhurstHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-4474-9668
Allan BalmainHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-6549-7861

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
PROMINENT - UCSFOT2CA278665 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2022 to 2026
$8.9M
Systems genetics analysis of tumor evolution in the mouseR35CA210018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2017 to 2026
$8.0M
PREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3M
Diversity Supplement to "Biomarkers, mechanisms and modulation of oxidative stress associated risk factors in carcinogenesis"DP5OD033424 · OD · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LI, YUN ROSE · 2022 to 2025
$2.1M
Genetic analysis of ras mutation specificity in skin and lung cancerR01CA184510 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN · 2015 to 2017
$1.1M
Single cell analysis of the evolving mutational landscape in carcinogen exposed skinR50CA251479 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANDYBA, EVE · 2020 to 2023
$397k
Examining the impact of the obesity-inflammation axis on cancer by genomic and transcriptomic profilingF32CA232635 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, YUN ROSE · 2018 to 2020
$202k
Selection of oncogenic Ras mutations through tumor promotion mechanismsF31CA271737 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOLLAM, SAUMYA REDDY · 2022 to 2024
$77k
Cancer Research UK CGCATF-2021/100007NCI NIH HHS F31 CA271737NCI NIH HHS F32 CA232635NCI NIH HHS OT2 CA278665NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA184510NCI NIH HHS R35 CA210018NCI NIH HHS R50 CA251479NIGMS NIH HHS T32 GM008568
6 · The paper itself

Abstract

Stem cells play a critical role in cancer development by contributing to cell heterogeneity, lineage plasticity, and drug resistance. We created gene expression networks from hundreds of mouse tissue samples (both normal and tumor) and integrated these with lineage tracing and single-cell RNA-seq, to identify convergence of cell states in premalignant tumor cells expressing markers of lineage plasticity and drug resistance. Two of these cell states representing multilineage plasticity or proliferation were inversely correlated, suggesting a mutually exclusive relationship. Treatment of carcinomas in vivo with chemotherapy repressed the proliferative state and activated multilineage plasticity whereas inhibition of differentiation repressed plasticity and potentiated responses to cell cycle inhibitors. Manipulation of this cell state transition point may provide a source of potential combinatorial targets for cancer therapy.

Indexed as

Carcinoma, Squamous CellCell LineageNeoplastic Stem CellsSkin NeoplasmsAnimalsCell DifferentiationCell PlasticityCell ProliferationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGene Regulatory NetworksMiceRNA-SeqSingle-Cell Analysis

Identifiers

PMID38815020
PMCPMC13492313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.